Published in Kidney Int on May 28, 2008
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci (2010) 0.90
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Bisphophonates in CKD patients with low bone mineral density. ScientificWorldJournal (2013) 0.84
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis (2011) 0.79
Treatment of osteopenia. Rev Endocr Metab Disord (2012) 0.79
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf (2011) 0.77
Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int (2015) 0.77
Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005-2008: is treatment with bisphosphonates an option? Osteoporos Int (2014) 0.76
Treatment of osteoporosis in renal insufficiency. Clin Rheumatol (2015) 0.76
Annual zoledronic acid did not increase renal abnormalities at 2 years in postmenopausal women with osteoporosis. ACP J Club (2008) 0.75
Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women. Kidney Int (2008) 0.75
Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis. J Clin Diagn Res (2016) 0.75
Early onset acute tubular necrosis following single infusion of zoledronate. Clin Cases Miner Bone Metab (2016) 0.75
[Dosage and toxicity of antirheumatic drugs in renal insufficiency]. Z Rheumatol (2015) 0.75
Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. Br J Clin Pharmacol (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care (2007) 2.39
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res (2003) 2.38
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Dietary glycemic index and glycemic load and the risk of type 2 diabetes in older adults. Am J Clin Nutr (2008) 2.08
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Estimation of the net acid load of the diet of ancestral preagricultural Homo sapiens and their hominid ancestors. Am J Clin Nutr (2002) 1.98
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos Int (2004) 1.83
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79
Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women > or =70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res (2006) 1.78
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res (2004) 1.76
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol (2004) 1.68
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
White-rot fungi demonstrate first biodegradation of phenolic resin. Environ Sci Technol (2006) 1.64
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab (2011) 1.59
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly (2008) 1.52
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res (2005) 1.42
Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res (2011) 1.40
Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.38
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cycles. Clin Chem (2005) 1.34
Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res (2004) 1.33
Diabetes, fracture, and bone fragility. Curr Osteoporos Rep (2007) 1.29
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Changes in flexed posture, musculoskeletal impairments, and physical performance after group exercise in community-dwelling older women. Arch Phys Med Rehabil (2007) 1.24
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception (2006) 1.21
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab (2005) 1.19
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2015) 1.18
Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther (2004) 1.17
Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res (2004) 1.17
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone (2005) 1.17
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res (2009) 1.17
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem (2001) 1.15
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin (2004) 1.15
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res (2011) 1.14
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab (2005) 1.14
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.12
Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res (2007) 1.12
Fat infiltration of muscle, diabetes, and clinical fracture risk in older adults. J Clin Endocrinol Metab (2010) 1.09
Prevalence and densitometric characteristics of incomplete distal renal tubular acidosis in men with recurrent calcium nephrolithiasis. Urol Res (2011) 1.09
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Secondary and tertiary hyperparathyroidism. J Clin Densitom (2012) 1.07
It's hard to be a real doctor now. Pharos Alpha Omega Alpha Honor Med Soc (2015) 1.07
Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care (2012) 1.07
Age-related hyperkyphosis: its causes, consequences, and management. J Orthop Sports Phys Ther (2010) 1.06
NIH consensus development conference statement: Lactose intolerance and health. NIH Consens State Sci Statements (2010) 1.05
Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res (2011) 1.05
Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.04
Eccentric exercise in coronary patients: central hemodynamic and metabolic responses. Med Sci Sports Exerc (2003) 1.04
Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res (2009) 1.04
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab (2011) 1.03
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective. J Bone Miner Res (2012) 1.03
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res (2009) 1.03
Safety of bisphosphonates in the treatment of osteoporosis. Am J Med (2009) 1.02
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord (2011) 1.01
Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women. J Bone Miner Res (2013) 1.01
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res (2004) 1.00
Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res (2010) 0.99
A model of osteoporosis impact in Switzerland 2000-2020. Osteoporos Int (2004) 0.99
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin (2006) 0.99
Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res (2013) 0.98
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin (2005) 0.98
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res (2011) 0.97
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care (2004) 0.97
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis (2011) 0.96
Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. J Clin Densitom (2002) 0.95